CR20250505A - Unión de anticuerpos multiespecíficos a bcma (divisional 2022-0656) - Google Patents
Unión de anticuerpos multiespecíficos a bcma (divisional 2022-0656)Info
- Publication number
- CR20250505A CR20250505A CR20250505A CR20250505A CR20250505A CR 20250505 A CR20250505 A CR 20250505A CR 20250505 A CR20250505 A CR 20250505A CR 20250505 A CR20250505 A CR 20250505A CR 20250505 A CR20250505 A CR 20250505A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bcma
- divisional
- binding
- specific antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046477P | 2020-06-30 | 2020-06-30 | |
| PCT/US2021/039961 WO2022006316A1 (en) | 2020-06-30 | 2021-06-30 | Multi-specific antibodies binding to bcma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250505A true CR20250505A (es) | 2026-01-13 |
Family
ID=77127069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250505A CR20250505A (es) | 2020-06-30 | 2021-06-30 | Unión de anticuerpos multiespecíficos a bcma (divisional 2022-0656) |
| CR20220656A CR20220656A (es) | 2020-06-30 | 2021-06-30 | Unión de anticuerpos multiespecíficos a bcma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220656A CR20220656A (es) | 2020-06-30 | 2021-06-30 | Unión de anticuerpos multiespecíficos a bcma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230257473A1 (enExample) |
| EP (1) | EP4171750A1 (enExample) |
| JP (2) | JP2023532129A (enExample) |
| KR (1) | KR20230038211A (enExample) |
| CN (1) | CN116472049A (enExample) |
| AU (1) | AU2021300179A1 (enExample) |
| BR (1) | BR112022027101A2 (enExample) |
| CA (1) | CA3189297A1 (enExample) |
| CL (1) | CL2022003754A1 (enExample) |
| CO (1) | CO2023000808A2 (enExample) |
| CR (2) | CR20250505A (enExample) |
| IL (1) | IL299027A (enExample) |
| JO (1) | JOP20220357A1 (enExample) |
| MX (1) | MX2022016342A (enExample) |
| PE (1) | PE20230464A1 (enExample) |
| WO (1) | WO2022006316A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| EA202091557A1 (ru) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
| CA3133654A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2024117786A1 (ko) | 2022-12-02 | 2024-06-06 | 주식회사 엘지에너지솔루션 | 배터리 팩 및 그의 제조 방법 |
| AU2024295287A1 (en) * | 2023-07-13 | 2025-10-16 | Telix Pharmaceuticals (Innovations) Pty Ltd | Humanised antibodies and uses thereof |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| AU6232899A (en) | 1999-10-06 | 2001-05-10 | Campina Melkunie B.V. | Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EP1776383B1 (en) | 2004-07-22 | 2014-08-20 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| DE102010039018B4 (de) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La Antikörper und ihre Anwendung zum Immunotargeting |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| CA3065133A1 (en) | 2017-06-09 | 2018-12-13 | Gemoab Monoclonals Gmbh | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders |
| JP7240335B2 (ja) * | 2017-06-20 | 2023-03-15 | テネオワン， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| CN110891971B (zh) * | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2019006072A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS |
| EP3581200A1 (en) * | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
-
2021
- 2021-06-30 IL IL299027A patent/IL299027A/en unknown
- 2021-06-30 MX MX2022016342A patent/MX2022016342A/es unknown
- 2021-06-30 WO PCT/US2021/039961 patent/WO2022006316A1/en not_active Ceased
- 2021-06-30 KR KR1020237003291A patent/KR20230038211A/ko active Pending
- 2021-06-30 BR BR112022027101A patent/BR112022027101A2/pt unknown
- 2021-06-30 AU AU2021300179A patent/AU2021300179A1/en active Pending
- 2021-06-30 CA CA3189297A patent/CA3189297A1/en active Pending
- 2021-06-30 JP JP2022581401A patent/JP2023532129A/ja active Pending
- 2021-06-30 PE PE2022003030A patent/PE20230464A1/es unknown
- 2021-06-30 US US18/002,472 patent/US20230257473A1/en active Pending
- 2021-06-30 EP EP21748714.9A patent/EP4171750A1/en active Pending
- 2021-06-30 CR CR20250505A patent/CR20250505A/es unknown
- 2021-06-30 CN CN202180052312.5A patent/CN116472049A/zh active Pending
- 2021-06-30 CR CR20220656A patent/CR20220656A/es unknown
-
2022
- 2022-12-26 CL CL2022003754A patent/CL2022003754A1/es unknown
- 2022-12-29 JO JOJO/P/2022/0357A patent/JOP20220357A1/ar unknown
-
2023
- 2023-01-25 CO CONC2023/0000808A patent/CO2023000808A2/es unknown
-
2025
- 2025-12-22 JP JP2025272312A patent/JP2026071208A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023532129A (ja) | 2023-07-26 |
| CL2022003754A1 (es) | 2023-07-07 |
| PE20230464A1 (es) | 2023-03-14 |
| CO2023000808A2 (es) | 2023-02-16 |
| CR20220656A (es) | 2023-03-01 |
| JOP20220357A1 (ar) | 2022-12-29 |
| KR20230038211A (ko) | 2023-03-17 |
| AU2021300179A1 (en) | 2023-02-02 |
| BR112022027101A2 (pt) | 2023-03-14 |
| MX2022016342A (es) | 2023-01-24 |
| CN116472049A (zh) | 2023-07-21 |
| EP4171750A1 (en) | 2023-05-03 |
| WO2022006316A1 (en) | 2022-01-06 |
| CA3189297A1 (en) | 2022-01-06 |
| JP2026071208A (ja) | 2026-04-28 |
| US20230257473A1 (en) | 2023-08-17 |
| IL299027A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023000808A2 (es) | Unión de anticuerpos multiespecíficos a bcma | |
| UY38748A (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| CL2025003689A1 (es) | Anticuerpos de cadena pesada que se unen al psma. | |
| AR122018A1 (es) | Proteínas que se unen a nkg2d, cd16 y clec12a | |
| ECSP22083174A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| MX2021014164A (es) | Moleculas de union a cd19 y usos de las mismas. | |
| MX2020002626A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores. | |
| CO2023000055A2 (es) | Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2 | |
| MX2020008736A (es) | Formulaciones de anticuerpos b7-h4. | |
| BR112023002116A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e egfr | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| PE20240591A1 (es) | Anticuerpos anti-variable delta 1 de tcr multiespecificos | |
| CL2024001009A1 (es) | Anticuerpos de unión a cd30 y cd3 | |
| DOP2025000023A (es) | Proteínas de unión a nkg2d, cd16 y ceacam5 | |
| CL2024000578A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| CL2025003391A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| AR122120A1 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| AR127896A1 (es) | Proteínas que se unen a nkg2d, cd16 y 5t4 | |
| CL2025002685A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso. | |
| MX2025010218A (es) | Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso | |
| CL2023002284A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CL2024002258A1 (es) | Anticuerpo multiespecífico anti-cd3/cd19; método de producción; composición farmacéutica; y su uso. |